Literature DB >> 16133990

Quantification of immunoglobulin free light chains in cerebrospinal fluid by nephelometry.

Sophie Desplat-Jégo1, Lionel Feuillet, Jean Pelletier, Dominique Bernard, André Ali Chérif, José Boucraut.   

Abstract

Oligoclonal free light chains (FLC) banding has been described in multiple sclerosis (MS) and should be correlated with disease activity. However, discrepancies between studies have been reported because of differences in methods. A new quantitative, rapid, and automated method using nephelometry is now available. Our objective was to investigate the interest of this method for the diagnosis and prognosis of MS. For this purpose, FLC index was determined in paired samples of CSF and serum from consecutive and unselected patients from the same department of neurology. We enrolled 89 patients (33 MS, 15 "possible MS", and 41 controls) and correlated with IgG index, IgG oligoclonal banding, and clinical MS progression criteria. The main results were (1) FLC kappa index was more sensitive but less specific than IgG index for the diagnosis of MS, (2) two MS patients were negative for oligoclonal banding but exhibited a positive kappa index, (3) no relation between FLC kappa indices, MS clinical criteria, and disease progression was found. In conclusion, FLC kappa index should be considered as a useful complementary test for MS diagnosis. Its pronostic interest remains to be determined on a larger cohort of possible MS patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16133990     DOI: 10.1007/s10875-005-5371-9

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  38 in total

1.  sICAM-1 is not a marker for disease activity in the relapse-free interval of multiple sclerosis--a cross-sectional pilot study.

Authors:  Peter Flachenecker; Stefan Jung; Peter Rieckmann; Klaus V Toyka
Journal:  J Neurol       Date:  2002-08       Impact factor: 4.849

2.  Free kappa light chains in multiple sclerosis spinal fluid.

Authors:  R A Rudick; A Pallant; J M Bidlack; R M Herndon
Journal:  Ann Neurol       Date:  1986-07       Impact factor: 10.422

3.  Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values.

Authors:  G Tibbling; H Link; S Ohman
Journal:  Scand J Clin Lab Invest       Date:  1977-09       Impact factor: 1.713

4.  Immunoglobulin free light chain assay using latex agglutination.

Authors:  K Wakasugi; H Suzuki; A Imai; S Konishi; H Kishioka
Journal:  Int J Clin Lab Res       Date:  1995

5.  Free light chains in multiple sclerosis and infections of the CNS.

Authors:  C DeCarli; M A Menegus; R A Rudick
Journal:  Neurology       Date:  1987-08       Impact factor: 9.910

6.  Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.

Authors:  R A Rudick; D L Cookfair; N A Simonian; R M Ransohoff; J R Richert; L D Jacobs; R M Herndon; A M Salazar; J S Fischer; C V Granger; D E Goodkin; J H Simon; D M Bartoszak; D N Bourdette; J Braiman; C M Brownscheidle; M E Coats; S L Cohan; D S Dougherty; R P Kinkel; M K Mass; F E Munchsauer; K O'Reilly; R L Priore; R H Whitham
Journal:  J Neuroimmunol       Date:  1999-01-01       Impact factor: 3.478

Review 7.  Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report.

Authors:  M Andersson; J Alvarez-Cermeño; G Bernardi; I Cogato; P Fredman; J Frederiksen; S Fredrikson; P Gallo; L M Grimaldi; M Grønning
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-08       Impact factor: 10.154

Review 8.  Body fluid markers to monitor multiple sclerosis: the assays and the challenges.

Authors:  J D Laman; E J Thompson; L Kappos
Journal:  Mult Scler       Date:  1998-06       Impact factor: 6.312

9.  Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains.

Authors:  Jerry A Katzmann; Raynell J Clark; Roshini S Abraham; Sandra Bryant; James F Lymp; Arthur R Bradwell; Robert A Kyle
Journal:  Clin Chem       Date:  2002-09       Impact factor: 8.327

10.  Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.

Authors:  W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422

View more
  17 in total

Review 1.  Body fluid biomarkers for multiple sclerosis--the long road to clinical application.

Authors:  Charlotte E Teunissen; Arjan Malekzadeh; Cyra Leurs; Claire Bridel; Joep Killestein
Journal:  Nat Rev Neurol       Date:  2015-09-22       Impact factor: 42.937

2.  Elevated levels of kappa free light chains in CSF support the diagnosis of multiple sclerosis.

Authors:  Stefan Presslauer; Dejan Milosavljevic; Thomas Brücke; Peter Bayer; Wolfgang Hübl; Walter Hübl
Journal:  J Neurol       Date:  2008-07-17       Impact factor: 4.849

3.  Cerebrospinal fluid markers reveal intrathecal inflammation in progressive multiple sclerosis.

Authors:  Mika Komori; Andrew Blake; Mark Greenwood; Yen Chih Lin; Peter Kosa; Danish Ghazali; Paige Winokur; Muktha Natrajan; Simone C Wuest; Elena Romm; Anil A Panackal; Peter R Williamson; Tianxia Wu; Bibiana Bielekova
Journal:  Ann Neurol       Date:  2015-04-16       Impact factor: 10.422

4.  Alteration of CD1 expression in multiple sclerosis.

Authors:  S Bine; A Haziot; I Malikova; J Pelletier; D Charron; J Boucraut; N Mooney; C Gelin
Journal:  Clin Exp Immunol       Date:  2012-07       Impact factor: 4.330

5.  Immunoglobulin free light chains in saliva: a potential marker for disease activity in multiple sclerosis.

Authors:  B Kaplan; S Golderman; E Ganelin-Cohen; A Miniovitch; E Korf; I Ben-Zvi; A Livneh; S Flechter
Journal:  Clin Exp Immunol       Date:  2017-12-26       Impact factor: 4.330

6.  Detection of oligoclonal IgG kappa and IgG lambda bands in cerebrospinal fluid and serum with Hevylite™ antibodies. comparison with the free light chain oligoclonal pattern.

Authors:  David Zeman; Pavel Hradílek; Zdeněk Svagera; Eva Mojžíšková; Ivana Woznicová; Olga Zapletalová
Journal:  Fluids Barriers CNS       Date:  2012-02-23

7.  Kappa free light chains: diagnostic and prognostic relevance in MS and CIS.

Authors:  Stefan Presslauer; Dejan Milosavljevic; Wolfgang Huebl; Silvia Parigger; Gabriele Schneider-Koch; Thomas Bruecke
Journal:  PLoS One       Date:  2014-02-25       Impact factor: 3.240

8.  Assessment of Intrathecal Free Light Chain Synthesis: Comparison of Different Quantitative Methods with the Detection of Oligoclonal Free Light Chains by Isoelectric Focusing and Affinity-Mediated Immunoblotting.

Authors:  David Zeman; Pavlína Kušnierová; Zdeněk Švagera; František Všianský; Monika Byrtusová; Pavel Hradílek; Barbora Kurková; Olga Zapletalová; Vladimír Bartoš
Journal:  PLoS One       Date:  2016-11-15       Impact factor: 3.240

9.  Free Light Chains and Intrathecal B Cells Activity in Multiple Sclerosis: A Prospective Study and Meta-Analysis.

Authors:  Gabriella Passerini; Gloria Dalla Costa; Francesca Sangalli; Lucia Moiola; Bruno Colombo; Massimo Locatelli; Giancarlo Comi; Roberto Furlan; Vittorio Martinelli
Journal:  Mult Scler Int       Date:  2016-12-28

10.  Cerebrospinal fluid immunoglobulin kappa light chain in clinically isolated syndrome and multiple sclerosis.

Authors:  Makbule Senel; Hayrettin Tumani; Florian Lauda; Stefan Presslauer; Rehaneh Mojib-Yezdani; Markus Otto; Johannes Brettschneider
Journal:  PLoS One       Date:  2014-04-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.